Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Observational 3Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 90Lymphoid 68Myeloid 16Tumor-Agnostic 15Plasma cell 13Breast 13Gastrointestinal 12Thoracic 9Classical hematology 3Sarcoma 2Gynecologic 2Dermatologic 2CNS 2Head & Neck 1Genitourinary 1

Conditions

Sarcoma 1336Glioblastoma 493Gliosarcoma 470Osteosarcoma 363Brain Neoplasms 321Central Nervous System Neoplasms 276Astrocytoma 262Dendritic Cell Sarcoma, Interdigitating 258Gastrointestinal Stromal Tumors 251Neoplasms 231Glioma 229Lymphoma 226Neuroblastoma 209Rhabdomyosarcoma 208Breast Neoplasms 204Sarcoma, Ewing 202Recurrence 202Burkitt Lymphoma 198Lymphoma, Non-Hodgkin 196Precursor Cell Lymphoblastic Leukemia-Lymphoma 195Oligodendroglioma 192Melanoma 182Ovarian Neoplasms 175Lymphoma, Large B-Cell, Diffuse 173Neoplasm Metastasis 172Bone Neoplasms 168Lymphoma, Follicular 158Leukemia, Lymphocytic, Chronic, B-Cell 144Lymphoma, Mantle-Cell 143Liposarcoma 143

Interventions

Cyclophosphamide 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasm, Residual × Sarcoma × Clear all
NCT02988466 2025-05-28

Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
78 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cellSarcoma

Bone Marrow Failure Disorders, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Follicular, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Neoplasm, Residual, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Primary Myelofibrosis

NCT02054104 2022-01-26

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
21 enrolled 11 charts
DermatologicSarcoma

Melanoma, Sarcoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡